Elisabeth Wik

5.0k citations

76 papers · 4.2k · 2 hit papers · h-index 27

Impact in

Obstetrics and Gynecology top 0.5%
- Endometrial and Cervical Cancer Treatments
Cancer Research top 2%
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies

Papers in

Obstetrics and Gynecology 22
- Endometrial and Cervical Cancer Treatments 21
Cancer Research 17
- Breast Cancer Treatment Studies 15

Co-authors: Helga Birgitte Salvesen (32 shared papers)Lars A. Akslen (43 shared papers)Jone Trovik (24 shared papers)Ingunn M. Stefansson (25 shared papers)Anne Margrete Oyan (15 shared papers)Henrica M.J. Werner (15 shared papers)Camilla Krakstad (14 shared papers)Even Birkeland (12 shared papers)
Journals: PLoS ONE (11 papers)Scientific Reports (5 papers)Clinical Cancer Research (5 papers)The Journal of Pathology Clinical Research (5 papers)Oncotarget (5 papers)
Partner nations: Norway United States United Kingdom

In The Last Decade

Elisabeth Wik

71 papers receiving 4.1k citations

Elisabeth Wik's Hit Papers

align trajectories log scale

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer 2013 · 468 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2013 Nature Genetics
2013 Nature

Peers

Countries citing papers authored by Elisabeth Wik

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Wik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Wik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Wik more than expected).

Fields of papers citing papers by Elisabeth Wik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Wik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Wik. The network helps show where Elisabeth Wik may publish in the future.

Co-authors

The 25 scholars most cited alongside Elisabeth Wik, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Elisabeth Wik Line = papers co-authored together Elisabeth Wik links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Landscape of genomic alterations in cervical carcinomas Nature ·Akinyemi I. Ojesina, Lee Lichtenstein, Samuel S. Freeman, Chandra Sekhar Pedamallu, Iván Imaz-Rosshandler, Trevor J. Pugh, Andrew D. Cherniack, Lauren Ambrogio Hit paper breakdown →	2013	732
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer Nature Genetics ·Australian Cancer Study, Stig E. Bojesen, Australian Ovarian Cancer Study, Gene Environment Interaction and Breast Cancer (GENICA), Swedish Breast Cancer Study (SWE-BRCA), Epidemiological study of BRCA1 & BRCA2 Mutation Carriers (EMBRACE), Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO), Karen A. Pooley Hit paper breakdown →	2013	468
3	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer Nature Genetics ·Paul D.P. Pharoah, Georgia Chenevix‐Trench, Ya-Yu Tsai, Susan J. Ramus, Catherine M. Phelan, Ellen L. Goode, Kate Lawrenson, Melissa A. Buckley	2013	299
4	Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation Proceedings of the National Academy of Sciences ·Helga Birgitte Salvesen, Scott L. Carter, Monica Mannelqvist, Amit Dutt, Gad A. Getz, Ingunn M. Stefansson, Maria Baroy Raeder, Martin L. Sos	2009	258
5	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer Nature Communications ·Hui Shen, Brooke L. Fridley, Honglin Song, Kate Lawrenson, Julie M. Cunningham, Susan J. Ramus, Mine S. Cicek, Jonathan P. Tyrer	2013	145
6	Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial European Journal of Cancer ·Jone Trovik, Elisabeth Wik, Henrica M.J. Werner, Camilla Krakstad, Harald Helland, Ingrid Vandenput, Tormund Salvesen Njølstad, Ingunn M. Stefansson	2013	138
7	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer Genome Medicine ·Andrew Erich Teschendorff, Shih‐Han Lee, Allison Jones, Heidi Fiegl, Marie Kalwa, Wolfgang Wagner, Kantaraja Chindera, Iona Evans	2015	138
8	Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses Oncotarget ·Geir Bredholt, Monica Mannelqvist, Ingunn M. Stefansson, Even Birkeland, Trond Hellem Bø, Anne Margrete Oyan, Jone Trovik, Karl‐Henning Kalland	2015	129
9	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development PLoS Medicine ·Allison Jones, Andrew Erich Teschendorff, Quanxi Li, Jane D. Hayward, Athilakshmi Kannan, Tim Mould, Michal Zikan, David Cibula	2013	128
10	Lack of Estrogen Receptor-α Is Associated with Epithelial–Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma Clinical Cancer Research ·Elisabeth Wik, Maria Baroy Raeder, Camilla Krakstad, Jone Trovik, Even Birkeland, Erling André Høivik, Siv Mjøs, Henrica M.J. Werner	2013	125
11	Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer Clinical Cancer Research ·Jone Trovik, Elisabeth Wik, Ingunn M. Stefansson, Janusz Marcickiewicz, Solveig Tingulstad, Anne Cathrine Staff, Tormund Salvesen Njølstad, Ingrid Vandenput	2011	108
12	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31 Nature Communications ·Jennifer Permuth‐Wey, Kate Lawrenson, Howard C. Shen, Aneliya Velkova, Jonathan P. Tyrer, Zhihua Chen, Hui‐Yi Lin, Y. Ann Chen	2013	97
13	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Molecular Cancer ·Lorena Alonso‐Alconada, Laura Muinelo‐Romay, Kadri Madissoo, Antonio Díaz‐López, Camilla Krakstad, Jone Trovik, Elisabeth Wik, Dharani Kosala Hapangama	2014	87
14	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer British Journal of Cancer ·Even Birkeland, Elisabeth Wik, Siv Mjøs, Erling André Høivik, Jone Trovik, Henrica M.J. Werner, Kanthida Kusonmano, Kjell Petersen	2012	77
15	Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers PLoS ONE ·Maria Baroy Raeder, Even Birkeland, Jone Trovik, Camilla Krakstad, Shyemaa Shehata, Steven E. Schumacher, Travis Ian Zack, Antje Krohn	2013	75
16	Elevated Plasma Growth Differentiation Factor-15 Correlates with Lymph Node Metastases and Poor Survival in Endometrial Cancer Clinical Cancer Research ·Anne Cathrine Staff, Jone Trovik, Elisabeth Wik, Kai Christoph Wollert, Tibor Kempf, Helga Birgitte Salvesen +1 other	2011	69
17	ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas Modern Pathology ·Henrica M.J. Werner, Anna Berg, Elisabeth Wik, Even Birkeland, Camilla Krakstad, Kanthida Kusonmano, Kjell Petersen, Karl Henning Kalland	2012	66
18	Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome British Journal of Cancer ·Camilla Krakstad, Jone Trovik, Elisabeth Wik, Ingeborg Bøe Engelsen, Henrica M.J. Werner, Einar Elvbakken Birkeland, Maria Baroy Raeder, Anne Margrete Oyan	2012	58
19	Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer Human Pathology ·Tor Audun Klingen, Ying Chen, Hans Aas, Elisabeth Wik, Lars A. Akslen	2017	56
20	Lipocalin 2 expression is associated with aggressive features of endometrial cancer BMC Cancer ·Monica Mannelqvist, Ingunn M. Stefansson, Elisabeth Wik, Kanthida Kusonmano, Maria Baroy Raeder, Anne Margrete Oyan, Karl‐Henning Kalland, Marsha A. Moses	2012	49

About Elisabeth Wik

Elisabeth Wik is a scholar working on Obstetrics and Gynecology, Cancer Research, Reproductive Medicine, Molecular Biology and Immunology, having authored 76 papers that have together received 4.2k indexed citations. Recurring topics across this work include Endometrial and Cervical Cancer Treatments (21 papers), Breast Cancer Treatment Studies (15 papers), Epigenetics and DNA Methylation (4 papers), Ovarian cancer diagnosis and treatment (4 papers), AI in cancer detection (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), Angiogenesis and VEGF in Cancer (2 papers) and Cervical Cancer and HPV Research (1 paper). The work is most often cited by research in Obstetrics and Gynecology (680 citations), Cancer Research (390 citations), Reproductive Medicine (223 citations), Genetics (335 citations) and Oncology (213 citations). Elisabeth Wik has collaborated with scholars based in Norway, United States and United Kingdom. Frequent co-authors include Helga Birgitte Salvesen, Lars A. Akslen, Jone Trovik, Ingunn M. Stefansson, Anne Margrete Oyan, Henrica M.J. Werner, Camilla Krakstad, Even Birkeland, Anne Cathrine Staff and Monica Mannelqvist. Their work appears in journals such as PLoS ONE, Scientific Reports, Clinical Cancer Research, The Journal of Pathology Clinical Research and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Elisabeth Wik

Impact in

Papers in i

In The Last Decade

Elisabeth Wik

Elisabeth Wik's Hit Papers

Peers

Countries citing papers authored by Elisabeth Wik

Fields of papers citing papers by Elisabeth Wik

All Works

About Elisabeth Wik

Explore authors with similar magnitude of impact

Papers in